课题基金 / 基金详情

Rapamycin enhanced efficacy of small-molecule HIV entry inhibitors

Rapamycin enhanced efficacy of small-molecule HIV entry inhibitors
雷帕霉素增强小分子 HIV 进入抑制剂的功效
批准号:
7548012
负责人:
Antony S. Dimitrov
金额:
$29.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-23 至 2010-06-30

项目摘要

项目成果

Antony S. Dimitrov的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):治疗HIV感染的较新方法试图通过靶向参与进入过程的不同蛋白质来阻断病毒进入细胞。进入抑制的可能靶点包括HIV包膜(Env)糖蛋白gp 120和gp 41、细胞受体CD 4以及趋化因子受体CCR 5和CXCR 4。临床试验已经证明了进入抑制剂的抗HIV潜力。然而,它们面临着与其他HAART药物相同的挑战-耐药病毒的快速生长和许多副作用。最近,发现细胞周期剂,如下调CCR 5受体的雷帕霉素,与进入抑制剂T20协同作用,T20是FDA批准的两种进入抑制剂之一,也称为Fuzeon或Enfuvirtide。我们的初步实验进一步证明,在体外加入雷帕霉素可以防止T20抗性病毒的出现,并增强其他抗性病毒对T20的易感性。我们还发现雷帕霉素与TAK-779(一种具有强效抗病毒活性的小分子CCR 5拮抗剂)协同作用并增强其抗HIV效率。这些观察结果表明,雷帕霉素可能增强其他进入抑制剂的治疗性能,如selzentry,称为maraviroc,与TAK-779一样,靶向CCR 5。Selzentry已于2007年8月6日获得FDA批准,用于与其他HAART药物联合抗HIV治疗。因此,本项目的目的是鉴定市场上和高级临床或临床前研究中的小分子进入抑制剂,这些抑制剂在雷帕霉素存在下显示出改善的抗HIV效率。我们提出通过以下3个目的来达到目标:目的1:鉴定哪些所选的小分子进入抑制剂与雷帕霉素协同抑制人PBMC中的病毒感染;目的2:证明加入雷帕霉素抑制剂抗性病毒的体外生长;目的3:证明加入雷帕霉素可以恢复抑制剂抗性病毒的易感性。如果我们在第一阶段项目中发现具有上述特征的化合物,我们的SBIR第二阶段提案将奋进开发一种口服雷帕霉素/进入抑制剂联合制剂来治疗艾滋病毒感染。本文件包含Profectus BioSciences要求不得向政府以外的人员发布的专有信息,除非用于审查和评估目的。雷帕霉素(Wyeth,麦迪逊,新泽西州)是一种免疫抑制药物,用于肾移植后口服。它是一种下调活化T细胞表面CCR 5表达的细胞周期因子。在体外,雷帕霉素增强了HIV进入抑制剂T20和TAK-779的疗效。这一观察结果表明,雷帕霉素还可以增强已经显示出合理生物利用度的小分子进入抑制剂的潜力。该项目的目的是确定口服生物可利用的进入抑制剂,这些抑制剂在市场上,接近市场或早期临床研究中,并与雷帕霉素协同抗HIV的效率。此类抑制剂将提供开发具有增强的抗病毒效率的新型口服给药制剂的机会。此类组合的临床前和临床开发将是后续SBIRs的主题。
英文摘要
DESCRIPTION (provided by applicant): Newer approaches to the treatment of HIV infection seek to block the entry of the virus into the cell by targeting different proteins engaged in the entry process. Possible targets for entry inhibition include the HIV envelope (Env) glycoproteins gp120 and gp41, the cellular receptor CD4, and the chemokine receptors CCR5 and CXCR4. Clinical trials have demonstrated anti-HIV potential of the entry inhibitors. However, they suffer from the same challenges as the other HAART drugs - rapid outgrowth of resistant virus and numerous side effects. Recently, cell cycle agents, such as rapamycin that downregulates the CCR5 receptor, were found to synergize with the entry inhibitor T20, one of the two entry inhibitors approved by the FDA, known also as Fuzeon or Enfuvirtide. Our preliminary experiments further demonstrate that the addition of rapamycin in vitro prevents the emergence of T20 resistant viruses and enhances the susceptibility to T20 of otherwise resistant viruses. We have also found that rapamycin synergizes with and enhances the anti-HIV efficiency of TAK-779, a small molecule CCR5 antagonist with potent antiviral activity. These observations suggest that rapamycin may enhance the therapeutic performance of other entry inhibitors such as selzentry, known as maraviroc, which, like TAK-779, targets CCR5. Selzentry has already been approved by the FDA on August 6, 2007 for anti-HIV therapy in combinations with other HAART drugs. The objective of this project, therefore, is to identify those small molecule entry inhibitors that are on the market and in advanced clinical or preclinical studies that show improved anti-HIV efficiency in the presence of rapamycin. We propose to reach the goal via the following 3 aims: Aim 1: Identify which of the selected small molecule entry inhibitors synergize with rapamycin to inhibit viral infections in human PBMCs; Aim 2: Demonstrate that the addition of rapamycin inhibits the outgrowth of inhibitor resistant viruses in vitro; Aim 3: Demonstrate that the addition of rapamycin can recover the susceptibility of the inhibitor resistant viruses. Should we identify compounds with the preceding characteristics during this Phase I project, our SBIR Phase II proposal will endeavor to develop an oral rapamycin/entry inhibitor co-formulation for treatment of HIV infection. This document contains proprietary information that Profectus BioSciences requests not be released to persons outside the Government, except for purposes of review and evaluation. PUBLIC HEALTH RELEVANCE Rapamycin (Wyeth, Madison, NJ) is an immunosuppressant drug prescribed for oral use after kidney transplantation. It is a cell cycle agent that downregulates the expression of CCR5 on the surface of activated T cells. In vitro, rapamycin enhances the efficacy of HIV entry inhibitors: T20 and TAK-779. This observation suggests that rapamycin may also enhance the potential of small molecule entry inhibitors that have already shown reasonable bioavailability. The objective of this project is to identify orally bioavailable entry inhibitors that are on the market, near market or in early clinical studies and that synergize with rapamycin in their anti-HIV efficiency. Such inhibitors will provide opportunities to develop novel orally administered formulations with enhanced antiviral efficiency. Preclinical and clinical development of such combinations will be the subject of follow-on SBIRs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of sG as a human vaccine against Nipah/Hendra
  • 批准号:
    8837560
  • 项目类别:
  • 资助金额:
    $103.51万
  • 财政年份:
    2012
  • 负责人:
    Antony S. Dimitrov
  • 依托单位:
Development of sG as a human vaccine against Nipah/Hendra
  • 批准号:
    8463115
  • 项目类别:
  • 资助金额:
    $99.07万
  • 财政年份:
    2012
  • 负责人:
    Antony S. Dimitrov
  • 依托单位:
Development of sG as a human vaccine against Nipah/Hendra
  • 批准号:
    8268865
  • 项目类别:
  • 资助金额:
    $130.64万
  • 财政年份:
    2012
  • 负责人:
    Antony S. Dimitrov
  • 依托单位:
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody
  • 批准号:
    8452173
  • 项目类别:
  • 资助金额:
    $103.95万
  • 财政年份:
    2011
  • 负责人:
    Antony S. Dimitrov
  • 依托单位:
海外基金